Cytodyn Inc (CYDY)

[Blue Man]

Forgot this part: It's in red, bolded, and underlined...

Nader Pourhassan, CEO:
We had more serious adverse events. The number of serious adverse events in this study is a little bit tricky because the randomization was 2:1. Two patients in leronlimab versus one patient in placebo. So, to equate them, we multiply the number of events in placebo by two, so we can equate how they compared. When we do that,there was 70% of the SAEs had happened in the placebo. 70% of the AEs had happened in placebo. These are amazing results. And we are very excited to file for emergency use authorization in many different countries, and we are going to update the shareholders as this goes forward.